Results 1 to 10 of about 17,845 (225)

Dolutegravir concentrations in children receiving 3-month weekly isoniazid and rifapentine (3HP) for tuberculosis prevention [PDF]

Microbiology Spectrum
In Tuberculosis Trials Consortium Study 35, which investigated the optimal dosing and safety of once-weekly isoniazid and rifapentine (3HP) in 69 children requiring tuberculosis preventive therapy, 7 children with HIV received 50 mg of once-daily ...
Ruvarashe J. Madzime, Louvina van der Laan, Samantha du Toit, Shaun Barnabas, Ingrid Courtney, Nicole E. Brown, Rada Savic, Belen P. Solans, Meredith G. Dixon, Lufina Tsirizani, Paolo Denti, Rosanna Boyd, Anneke C. Hesseling   +12 more
doaj   +3 more sources

Dolutegravir + Lamivudine vs. Dolutegravir + Tenofovir Disoproxil Fumarate/Emtricitabine: Very-Low-Level HIV-1 Replication through 144 Weeks in the GEMINI-1 and GEMINI-2 Studies

Viruses
In GEMINI-1/-2, dolutegravir + lamivudine was non-inferior to dolutegravir + tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) in achieving viral suppression (viral load [VL] < 50 copies/mL) in treatment-naive adults.
Mark Underwood, Rimgaile Urbaityte, Ruolan Wang, Joe Horton, James Oyee, Brian Wynne, Dainielle Fox, Bryn Jones, Choy Man, Jörg Sievers   +9 more
doaj   +3 more sources

Enhanced Eryptosis Following Exposure to Dolutegravir [PDF]

Cellular Physiology and Biochemistry, 2016
Background/Aims: The viral integrase enzyme inhibitor dolutegravir is utilized for the treatment of immunodeficiency virus (HIV) infection. Knowledge on cytotoxicity of dolutegravir is limited.
Abdulla Al Mamun Bhuyan, Elena Signoretto, Rosi Bissinger, Florian Lang   +3 more
doaj   +2 more sources

Dolutegravir-associated hyperglycemia: a narrative review [PDF]

AIDS Research and Therapy
Dolutegravir is a preferred antiretroviral drug given its high resistance barrier and efficacy; however, reports from sub-Saharan Africa indicate increased hyperglycemia rates among individuals living with HIV on dolutegravir.
Allan Buzibye, Barbara Castelnuovo, Robert C. Bollinger, Joseph Ssebulime, Denis Omali, Daniel Muller, Frank Mulindwa, Eva Laker, Catriona Waitt, Irene Andia, Mohammed Lamorde, Ahmet Hoke, Bernard S. Bagaya, Yukari C. Manabe   +13 more
doaj   +2 more sources

SLC22A2 variants and dolutegravir levels correlate with psychiatric symptoms in persons with HIV [PDF]

Journal of Antimicrobial Chemotherapy, 2019
Background: Neuropsychiatric symptoms (NPs) have been reported with dolutegravir use. We hypothesized that increasing dolutegravir trough concentrations (Ctrough) and/or polymorphism in the SLC22A2 gene, encoding the organic cation transporter-2 (OCT2 ...
Andrea Calcagno, Francesca Lombardi, Jessica Cusato   +2 more
exaly   +3 more sources

Pharmacokinetics of dolutegravir, tenofovir and lamivudine during venous-venous extracorporeal membrane oxygenation (VV-ECMO): A case report. [PDF]

Br J Clin Pharmacol
While providing potentially life‐saving cardiorespiratory support for critically ill patients, extracorporeal membrane oxygenation (ECMO) may detrimentally affect pharmacokinetic (PK) performance and concurrent drug efficacy and safety. We describe a patient with Pneumocystis jirovecii pneumonia (PJP) in the context of acquired immunodeficiency ...
Zwart TC, Leegwater E, Ottens TH, Schippers EF, Wilms EB, Burger DM, van Nieuwkoop C, Bosma LBE.   +7 more
europepmc   +2 more sources

Impact of treatment adherence on efficacy of dolutegravir plus lamivudine and dolutegravir plus tenofovir disoproxil fumarate/emtricitabine: pooled analysis of the GEMINI-1 and GEMINI-2 clinical studies

HIV Research & Clinical Practice, 2021
Background: GEMINI-1 and GEMINI-2 (ClinicalTrials.gov, NCT02831673 and NCT02831764, respectively) are double-blind, multicenter, phase III studies that demonstrated the non-inferiority of once-daily dolutegravir + lamivudine to dolutegravir + tenofovir ...
Mounir Ait-Khaled, Juan Sierra Madero, Vicente Estrada, Roberto Gulminetti, Debbie Hagins, Hung-Chin Tsai, Choy Man, Jörg Sievers, Richard Grove, Andrew Zolopa, Brian Wynne, Jean van Wyk   +11 more
doaj   +2 more sources

Potential benefit of dolutegravir once daily: efficacy and safety

HIV/AIDS: Research and Palliative Care, 2013
Alessandra Fantauzzi,1 Ombretta Turriziani,2 Ivano Mezzaroma11Department of Clinical Medicine, 2Department of Molecular Medicine, Sapienza, University of Rome, Rome, ItalyAbstract: The viral integrase enzyme has recently emerged as a primary alternative ...
Fantauzzi A, Turriziani O, Mezzaroma I
doaj   +2 more sources

Perceptions of dolutegravir-based regimen use among people living with HIV in Limpopo province: A qualitative study [PDF]

Curationis
Background: HIV and AIDS continues to be a critical public health challenge, with sub-Saharan Africa shouldering the heaviest burden. Progress towards disease management has been implemented over the years, and antiretroviral therapy (ART) has been the ...
Zandile R. Sibeko, Boitumelo J. Molato, Salaminah S.P. Moloko-Phiri   +2 more
doaj   +2 more sources

Dolutegravir – a review of the pharmacology, efficacy, and safety in the treatment of HIV

Drug Design, Development and Therapy, 2015
Christopher E Kandel,1 Sharon L Walmsley1,21Department of Medicine, University of Toronto, Toronto, ON, Canada; 2Division of Infectious Diseases, University Health Network, Toronto, ON, CanadaAbstract: Dolutegravir is the newest integrase strand transfer
Kandel CE, Walmsley SL
doaj   +2 more sources